We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.
Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.
Corporate profile
Press Releases
![](https://www.maatpharma.com/wp-content/uploads/2021/12/Website_maat_logo-600x403.png)
July 5, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
![](https://www.maatpharma.com/wp-content/uploads/2021/12/Website_maat_logo-140x140.png)
July 5, 2024: MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux
![](https://www.maatpharma.com/wp-content/uploads/2021/12/Website_maat_logo-140x140.png)
July 2, 2024: MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
Media Coverage
![](https://www.maatpharma.com/wp-content/uploads/2024/01/9-1-140x140.png)
December 21, 2023: MaaT Pharma et Skyepharma mettent en service leur usine de médicaments à base de microbiote – Les Echos (French only)
![](https://www.maatpharma.com/wp-content/uploads/2024/01/Logos-site-web-140x140.png)
December 18, 2023: Microbiome-based treatment shows potential in graft-versus-host disease – BioPharma reporter
![](https://www.maatpharma.com/wp-content/uploads/2024/01/10-1-140x140.png)
December 11, 2023: ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease – EPR
Posters
![](https://www.maatpharma.com/wp-content/uploads/2024/06/ENCALS_logo_pay-off_RGB_300dpi-e1502445007959.png)
Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial
![](https://www.maatpharma.com/wp-content/uploads/2023/04/ebmt-share-1-140x140.png)
A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial
![](https://www.maatpharma.com/wp-content/uploads/2024/03/Website_AACR-140x140.jpg)
Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
![](https://www.maatpharma.com/wp-content/uploads/2022/06/Website_maat_logo-140x140.png)